These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 1337634)

  • 21. Injectable paromomycin for Visceral leishmaniasis in India.
    Sundar S; Jha TK; Thakur CP; Sinha PK; Bhattacharya SK
    N Engl J Med; 2007 Jun; 356(25):2571-81. PubMed ID: 17582067
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The treatment of visceral leishmaniasis (kala-azar) in India: no obvious signs of long-term success.
    Muniaraj M; Paramasivan R; Mariappan T; Arunachalam N; Sinha PK
    Trans R Soc Trop Med Hyg; 2012 Dec; 106(12):770-2. PubMed ID: 23102868
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Kala-azar: unresponsiveness to prolonged sodium stibogluconate therapy.
    Bhattacharya D; Majhi TK; Dutta RK
    J Assoc Physicians India; 1987 Jul; 35(7):543. PubMed ID: 2828305
    [No Abstract]   [Full Text] [Related]  

  • 24. Comparison of treatment regimens of kala-azar based on culture & sensitivity of amastigotes to sodium antimony gluconate.
    Thakur CP; Thakur S; Narayan S; Sinha A
    Indian J Med Res; 2008 Jun; 127(6):582-8. PubMed ID: 18765878
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The treatment of kala-azar in the Sudan with sodium stibogluconate: a randomized trial of three dosage regimens.
    Zijlstra EE; Siddig Ali M; el-Hassan AM; Hofland HW; el-Toum I; Satti M; Ghalib HW
    Trans R Soc Trop Med Hyg; 1993; 87(3):307-9. PubMed ID: 8236402
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rationalisation of regimens of treatment of kala-azar with sodium stibogluconate in India: a randomised study.
    Thakur CP; Kumar M; Kumar P; Mishra BN; Pandey AK
    Br Med J (Clin Res Ed); 1988 Jun; 296(6636):1557-61. PubMed ID: 2840172
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum erythropoietin concentration in anaemia of visceral leishmaniasis (kala-azar) before and during antimonial therapy.
    Saeed AM; Khalil EA; Elhassan AM; Hashim FA; Elhassan AM; Fandrey J; Jelkmann W
    Br J Haematol; 1998 Mar; 100(4):720-4. PubMed ID: 9531339
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ketoconazole in antimonial unresponsive cases of Kala-azar.
    Jha TK; Singh NK; Jha S
    J Assoc Physicians India; 1995 May; 43(5):347. PubMed ID: 9081966
    [No Abstract]   [Full Text] [Related]  

  • 29. Amphotericin versus sodium stibogluconate in first-line treatment of Indian kala-azar.
    Mishra M; Biswas UK; Jha AM; Khan AB
    Lancet; 1994 Dec; 344(8937):1599-600. PubMed ID: 7983993
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Post kala-azar dermal leishmaniasis: the Kenyan experience.
    Muigai R; Gachihi GS; Oster CN; Were JB; Nyakundi PM; Chunge CN; Kirigi G; Rashid JR
    East Afr Med J; 1991 Oct; 68(10):801-6. PubMed ID: 1667521
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of kala-azar in southern Sudan using a 17-day regimen of sodium stibogluconate combined with paromomycin: a retrospective comparison with 30-day sodium stibogluconate monotherapy.
    Melaku Y; Collin SM; Keus K; Gatluak F; Ritmeijer K; Davidson RN
    Am J Trop Med Hyg; 2007 Jul; 77(1):89-94. PubMed ID: 17620635
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cumulative cardiac toxicity of sodium stibogluconate and amphotericin B in treatment of kala-azar.
    Maheshwari A; Seth A; Kaur S; Aneja S; Rath B; Basu S; Patel R; Dutta AK
    Pediatr Infect Dis J; 2011 Feb; 30(2):180-1. PubMed ID: 20823781
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine.
    Sangraula H; Sharma KK; Rijal S; Dwivedi S; Koirala S
    J Assoc Physicians India; 2003 Jul; 51():686-90. PubMed ID: 14621038
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Magnitude of unresponsiveness to sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar.
    Das VN; Ranjan A; Bimal S; Siddique NA; Pandey K; Kumar N; Verma N; Singh VP; Sinha PK; Bhattacharya SK
    Natl Med J India; 2005; 18(3):131-3. PubMed ID: 16130613
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug resistance in Indian visceral leishmaniasis.
    Sundar S
    Trop Med Int Health; 2001 Nov; 6(11):849-54. PubMed ID: 11703838
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Deaths in visceral leishmaniasis (Kala-azar) during treatment.
    Ahasan HA; Chowdhury MA; Azhar MA; Rafiqueuddin AK; Azad KA
    Med J Malaysia; 1996 Mar; 51(1):29-32. PubMed ID: 10967976
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of serum amylase, lipase and associated factors among patients with visceral leishmaniasis treated with sodium stibogluconate/paromomycin at University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia.
    Mengstie TA; Endale HT; Mulaw T; Abdella AM; Mohammed R; Malik T; Dessie G
    PLoS One; 2021; 16(10):e0257229. PubMed ID: 34597312
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.
    Sundar S; Sinha PK; Rai M; Verma DK; Nawin K; Alam S; Chakravarty J; Vaillant M; Verma N; Pandey K; Kumari P; Lal CS; Arora R; Sharma B; Ellis S; Strub-Wourgaft N; Balasegaram M; Olliaro P; Das P; Modabber F
    Lancet; 2011 Feb; 377(9764):477-86. PubMed ID: 21255828
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic.
    Sundar S; More DK; Singh MK; Singh VP; Sharma S; Makharia A; Kumar PC; Murray HW
    Clin Infect Dis; 2000 Oct; 31(4):1104-7. PubMed ID: 11049798
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India.
    Singh RP; Picado A; Alam S; Hasker E; Singh SP; Ostyn B; Chappuis F; Sundar S; Boelaert M
    Trop Med Int Health; 2012 Nov; 17(11):1345-8. PubMed ID: 22882665
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.